Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use.<br>Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.

Foundayo GLP-1 Pill: FDA Needs More Data

On The Pen GLP-1 News

# Full Transcript

**Podcast:** On The Pen GLP-1 News

## Participants

- **Dave Knapp** (GLP-1 Industry Insider)

## Transcript

What if I told you that one of the biggest risks to the GLP-1 category right now isn't access? It's how the next generation of these drugs behaves at scale and specifically how small molecule GLP-1s interact with the liver. When you move from peptide based GLP-1s to small molecule drugs, you introduce a different risk profile.

And the part that I think that many people gloss over when it comes to this is that if that signal actually shows up in the real world, it doesn't stay contained to that one drug. They're not going to say that was a small molecule issue. They're going to say that's a GLP-1 problem. And that's why what the FDA is doing right now matters a ton if you're paying attention to this space. Welcome back to On The Pen.

Welcome to the On The Pen podcast with your host, Dave Knapp. Welcome back to the On The Pen podcast. I'm your host, Dave Knapp, man on the Manjaro. That's why I'm here. You are on the pen. We go V, sex, Saxenda, Victoza, Trulicity, Mounjaro, ZepBound, Foundeo.

That pen or now pill is what we talk about each and every week here at On The Pen because we want to empower you to have more competent and confident conversations. With your doctor. So as you're jumping in here, if you're new and you're listening on the podcast, drop us a five star rating and review. If you're listening on YouTube, hit the thumbs up button, subscribe down below, hit the bell for notifications. And in the description of this video, there's a hype button. Give this a hype because it's going to help push this video out to other people who need it.

Now we talk all about obesity medicine here and access is one of the paramount topics that we talk about because what matters more than your ability to get the medication. And for that reason, we've chosen to partner with a company called Shed who sponsors our podcast. Now you can go to tryshed.com and learn more about treating the chronic and relapsing disease of obesity.

If you've talked to your doctor and felt flat out shut out of the conversation, you should check out Shed where they're going to connect you with a licensed medical provider who can talk you through what it's like to deal with your specific disease, the specific issues that you're dealing with and connect you potentially with medications that might help you treat the chronic disease of obesity. If you use code OTP25, it's going to save you 25%. Before you try any drug, you should familiarize yourself with potential risks and benefits at the same time.

And you can do all that by talking to a doctor at tryshed.com and saving 25% with code OTP25. Thank you to Shed for sponsoring the podcast. Now, as I said before, what is more paramount? What is more important to talk about than the topic of accessibility? But many things can affect accessibility, including the perception of these drugs and how they are ...

Foundayo GLP-1 Pill: FDA Needs More Data

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

Foundayo GLP-1 Pill: FDA Needs More Data

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.